Table 2.

Relative clinical advantages of therapies demonstrating improved survival in metastatic castration-resistant prostate cancer.

Therapy	Population	Advantages	Disadvantages
Docetaxel	Chemotherapy- naive	May improve symptoms related to mCRPC	- Common toxicities include myelosuppression, fatigue, dysgeusia, and neuropathy. - No clear data suggesting starting docetaxel earlier in mCRPC leads to better outcomes.
Sipuleucel-T 1	Chemotherapy- naïve	- Minimal symptoms related to therapy - Brief course of therapy (1 month)	- Lack of intermediate markers of response make it difficult to assess who will do well in the long term. - Less likely to be effective in patients with aggressive disease characteristics. - Production of vaccine is labor-intensive.
Cabazitaxel	Post-Docetaxel	- Survival benefit after progression on docetaxel	- Toxicity profile, including approximately 5% of treatment-related mortality.
Abiraterone 2	Post-Docetaxel	- Survival benefit after progression on docetaxel -Less severe toxicity than cabazitaxel - Oral administration	- Mineralocorticoid-related adverse events in > 30% of patients.

mCRPC = metastatic castration-resistant prostate cancer.

¹Evaluated in patients previously treated with chemotherapy. However, the authors believe this agent should be used primarily in chemotherapy-naive patients, as discussed in the text.

²Not currently FDA-approved at time of publication.